Adaptive Biotechnologies Corporation
ADPT
$2.66
$0.062.31%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 45.78M | 37.92M | 48.93M | 37.65M | 55.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.78M | 37.92M | 48.93M | 37.65M | 55.20M |
| Cost of Revenue | -53.29M | 47.88M | 50.15M | 51.28M | -76.26M |
| Gross Profit | 99.07M | -9.96M | -1.22M | -13.64M | 131.45M |
| SG&A Expenses | 42.63M | 40.57M | 46.17M | 43.14M | 46.14M |
| Depreciation & Amortization | 429.00K | 428.00K | 423.00K | 419.00K | 429.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.42M | 88.88M | 96.74M | 94.84M | 94.38M |
| Operating Income | -45.64M | -50.96M | -47.82M | -57.19M | -39.19M |
| Income Before Tax | -69.47M | -50.33M | -47.81M | -57.70M | -40.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.47M | -50.33M | -47.81M | -57.70M | -40.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 26.00K | 26.00K | 1.00K | 1.00K | 41.00K |
| Net Income | -69.44M | -50.30M | -47.81M | -57.70M | -40.13M |
| EBIT | -45.64M | -50.96M | -47.82M | -57.19M | -39.19M |
| EBITDA | -40.25M | -45.19M | -42.17M | -51.77M | -33.90M |
| EPS Basic | -0.48 | -0.35 | -0.33 | -0.40 | -0.28 |
| Normalized Basic EPS | -0.20 | -0.22 | -0.21 | -0.26 | -0.18 |
| EPS Diluted | -0.48 | -0.35 | -0.33 | -0.40 | -0.28 |
| Normalized Diluted EPS | -0.20 | -0.22 | -0.21 | -0.26 | -0.18 |
| Average Basic Shares Outstanding | 144.90M | 144.70M | 144.40M | 143.51M | 143.05M |
| Average Diluted Shares Outstanding | 144.90M | 144.70M | 144.40M | 143.51M | 143.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
